The Impact of Utilizing Different Optical Coherence Tomography Devices for Clinical Purposes and in Multiple Sclerosis Trials
Open Access
- 11 August 2011
- journal article
- clinical trial
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (8), e22947
- https://doi.org/10.1371/journal.pone.0022947
Abstract
Optical coherence tomography (OCT) derived retinal measures, particularly peri-papillary retinal nerve fiber layer (RNFL) thickness, have been proposed as outcome measures in remyelinating and neuroprotective trials in multiple sclerosis (MS). With increasing utilization of multiple centers to improve power, elucidation of the impact of different OCT technologies is crucial to the design and interpretation of such studies. In this study, we assessed relation and agreement between RNFL thickness and total macular volume (in MS and healthy controls) derived from three commonly used OCT devices: Stratus time-domain OCT, and Cirrus HD-OCT and Spectralis, two spectral-domain (SD) OCT devices. OCT was performed on both Cirrus HD-OCT and Stratus in 229 participants and on both Cirrus HD-OCT and Spectralis in a separate cohort of 102 participants. Pearson correlation and Bland-Altman analyses were used to assess correlation and agreement between devices. All OCT retinal measures correlated highly between devices. The mean RNFL thickness was 7.4 µm lower on Cirrus HD-OCT than Stratus, indicating overall poor agreement for this measurement between these machines. Further, the limits of agreement (LOA) between Cirrus HD-OCT and Stratus were wide (−4.1 to 18.9 µm), indicating poor agreement at an individual subject level. The mean RNFL thickness was 1.94 µm (LOA: −5.74 to 9.62 µm) higher on Spectralis compared to Cirrus HD-OCT, indicating excellent agreement for this measurement across this cohort. Although these data indicate that these three devices agree poorly at an individual subject level (evidenced by wide LOA in both study cohorts) precluding their co-utilization in everyday practice, the small difference for mean measurements between Cirrus HD-OCT and Spectralis indicate pooled results from these two SD-devices could be used as outcome measures in clinical trials, provided patients are scanned on the same machine throughout the trial, similar to the utilization of multiple different MRI platforms in MS clinical trials.Keywords
This publication has 72 references indexed in Scilit:
- Reproducibility and agreement in evaluating retinal nerve fibre layer thickness between Stratus and Spectralis OCTEye, 2010
- Radial diffusivity in remote optic neuritis discriminates visual outcomesNeurology, 2010
- Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosisAnnals of Neurology, 2010
- Comparison of Retinal Nerve Fiber Layer Measurements Using Time Domain and Spectral Domain Optical Coherent TomographyOphthalmology, 2009
- Agreement between spectral-domain and time-domain OCT for measuring RNFL thicknessBritish Journal of Ophthalmology, 2009
- Optical coherence tomography: a window into the mechanisms of multiple sclerosisNature Clinical Practice Neurology, 2008
- Inflammatory demyelination induces axonal injury and retinal ganglion cell apoptosis in experimental optic neuritisExperimental Eye Research, 2008
- Optical Coherence Tomography and Histologic Measurements of Nerve Fiber Layer Thickness in Normal and Glaucomatous Monkey EyesPublished by Association for Research in Vision and Ophthalmology (ARVO) ,2007
- Defining the clinical course of multiple sclerosisNeurology, 1996
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986